JPJavier Palazuelos

Javier Palazuelos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Javier Palazuelos has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neuronal Aralar/AGC1 deficiency impairs social behavior through dopaminergic and redox dysfunction and is rescued by β-hydroxybutyrate

    by Eduardo Herrada-Soler, Nerea Murugarren, Miguel Angel Serrano-Lope, María José Casarejos, Javier Palazuelos, Jorgina Satrústegui, Araceli del Arco, Beatriz Pardo

    Background: Pathogenic variants in SLC25A12/AGC1 (Aralar) have been linked to autism spectrum disorder (ASD), yet the mechanisms connecting neuronal metabolic dysfunction to altered social behavior remain poorly understood. Aralar is a key component of the malate-aspartate shuttle, supporting neuronal oxidative metabolism and lactate utilization. Here, we investigated the consequences of postnatal neuronal Aralar deletion and the therapeutic potential of β-hydroxybutyrate (BHB). Methods: We generated neuron-specific Aralar knockout mice (Neu Aralar-KO) using CamKIIα-Cre, producing efficient recombination in cortex, hippocampus, and striatum. Behavioral, transcriptomic, neurochemical, morphometric, histological, and biochemical analyses were performed in adult mice. The effects of systemic BHB administration were assessed using behavioral, metabolic, oxidative stress, and transcriptomic endpoints. Results: Despite a 55-65% reduction of Aralar expression in forebrain regions, Neu Aralar-KO mice displayed normal growth, survival, brain structure, and myelination. Unexpectedly, loss of neuronal Aralar did not impair spatial memory, episodic memory, or reversal learning. In contrast, Neu Aralar-KO mice exhibited hyperactivity and a marked deficit in sociability, revealing an ASD-relevant behavioral phenotype. Morphological analysis showed significant remodeling of striatal dendritic spines without changes in spine density. Transcriptomic profiling identified 433 differentially expressed genes, the vast majority being upregulated, with enrichment of pathways related to neuropeptide signaling, synaptic transmission, membrane excitability, and behavior. Notably, genes involved in dopamine (DA) and glutamate handling, synaptic connectivity, neuromodulatory signaling, and ASD-associated pathways were strongly induced. Neurochemical analyses revealed preserved glutamate and GABA levels but reduced striatal DA content accompanied by an increased DOPAC/DA ratio, indicating enhanced DA degradation. DAergic neurons of the ventral tegmental area (VTA) showed minimal recombination, suggesting that DA dysfunction arises through non-cell-autonomous mechanisms. Consistent with increased DA oxidative catabolism, Neu Aralar-KO striata displayed elevated lipid peroxidation, induction of glutathione-related pathways, upregulation of antioxidant genes, and astrocyte activation. Remarkably, BHB treatment restored sociability, normalized striatal metabolic alterations, reduced oxidative stress, and abolished genotype-dependent neurochemical abnormalities. Transcriptomic analyses further revealed that Aralar deficiency recapitulates a substantial fraction of the fasting/BHB-induced epigenetic transcriptional program. Conclusions: Postnatal neuronal Aralar deficiency uncouples social behavior from cognitive performance and drives ASD-like phenotypes through a mechanism linking neuronal metabolic dysfunction, oxidative stress, glial activation, and impaired DAergic homeostasis. The rescue of behavioral, metabolic, and redox abnormalities by BHB identifies restoration of metabolic homeostasis as a major therapeutic mechanism and highlights metabolic interventions as promising strategies for AGC1 deficiency and ASD-associated disorders involving neuronal metabolic dysfunction.

  • Open Access

    Cannabinoid CB1 receptors drive oligodendrocyte maturation during myelin regeneration

    by Sara Ezquerro-Herce, Aníbal Sánchez-De la Torre, Krisztina Monory, Beat Lutz, Manuel Guzmán, Tania Aguado, Javier Palazuelos

    Oligodendrocytes, the myelin-producing cells in the central nervous system, derive from oligodendrocyte progenitor cells during both development and remyel


  • CB1 receptors in NG2 cells mediate cannabinoid-evoked functional myelin regeneration

    by Aníbal Sánchez de la Torre, Sara Ezquerro-Herce, Alba Huerga-Gómez, Ester Sánchez-Martín, Juan Carlos Chara, Carlos Matute, Krisztina Monory, Susana Mato, Beat Lutz, Manuel Guzmán, et al.


  • Open Access

    NG2 CELLS MEDIATE CANNABINOID-INDUCED FUNCTIONAL RECOVERY FOLLOWING DEMYELINATION

    by Aníbal Sánchez-De La Torre, Sara Ezquerro, Rubén Díaz-Cita, Eva Resel, Carlos Matute, Krisztina Monory, Susana Mato, Beat Lutz, Ismael Galve-Roperh, Manuel Guzmán, et al.

  • Open Access

    Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice

    by Aníbal Sánchez-De la Torre, Tania Aguado, Alba Huerga-Gómez, Silvia Santamaría, Antonietta Gentile, Juan Carlos Chara, Carlos Matute, Krisztina Monory, Susana Mato, Manuel Guzmán, et al.

    Cannabinoids are known to modulate oligodendrogenesis and developmental CNS myelination. However, the cell-autonomous action of these compounds on oligodendroglial cells in vivo, and the molecular mechanisms underlying these effects have not yet been studied. Here, by using oligodendroglial precursor cell (OPC)-targeted genetic mouse models, we show that cannabinoid CB1 receptors exert an essential role in modulating OPC differentiation at the critical periods of postnatal myelination. We found that selective genetic inactivation of CB1 receptors in OPCs in vivo perturbs oligodendrogenesis and postnatal myelination by altering the RhoA/ROCK signaling pathway, leading to hypomyelination, and motor and cognitive alterations in young adult mice. Conversely, pharmacological CB1 receptor activation, by inducing E3 ubiquitin ligase-dependent RhoA proteasomal degradation, promotes oligodendrocyte development and CNS myelination in OPCs, an effect that was not evident in OPC-specific CB1 receptor-deficient mice. Moreover, pharmacological inactivation of ROCK in vivo overcomes the defects in oligodendrogenesis and CNS myelination, and behavioral alterations found in OPC-specific CB1 receptor-deficient mice. Overall, this study supports a cell-autonomous role for CB1 receptors in modulating oligodendrogenesis in vivo, which may have a profound impact on the scientific knowledge and therapeutic manipulation of CNS myelination by cannabinoids.


  • Open Access

    Δ9‐Tetrahydrocannabinol promotes functional remyelination in the mouse brain

    by Tania Aguado, Alba Huerga‐Gómez, Aníbal Sánchez‐De la Torre, Eva Resel, Juan Carlos Chara, Carlos Matute, Susana Mato, Ismael Galve‐Roperh, Manuel Guzman, Javier Palazuelos

    Background and purpose Research on demyelinating disorders aims to find novel molecules able to induce oligodendrocyte precursor cell differentiation to promote CNS remyelination and functional recovery. Δ9-Tetrahydrocannabinol (THC), the most prominent active constituent of the hemp plant Cannabis sativa, confers neuroprotection in animal models of demyelination. However, the possible effect of THC on myelin repair has never been studied. Experimental approach By using oligodendroglia-specific reporter mouse lines in combination with 2 models of toxin-induced demyelination, we analyzed the effect of THC on the processes of oligodendrocyte regeneration and functional remyelination. Key results We show that THC administration enhanced oligodendrocyte regeneration, white matter remyelination, and motor function recovery. THC also promoted axonal remyelination in organotypic cerebellar cultures. THC remyelinating action relied on the induction of oligodendrocyte precursor differentiation upon cell cycle exit and via CB1 cannabinoid receptor activation. Conclusions and implications Overall, our study identifies THC administration as a promising pharmacological strategy aimed to promote functional CNS remyelination in demyelinating disorders.


  • Open Access

    Δ 9 -Tetrahydrocannabinol Promotes Functional Remyelination in the Mouse Brain

    by Tania Aguado, Alba Huerga-Gómez, Aníbal Sánchez-De la Torre, Eva Resel, Juan Carlos Chara, Carlos Matute, Susana Mato, Ismael Galve-Roperh, Manuel Guzmán, Javier Palazuelos

    Background: Research on demyelinating disorders aims to find novel molecules able to induce oligodendrocyte precursor cell differentiation to promote CNS remyelination and functional recovery. Δ9-Tetrahydrocannabinol (THC), the most prominent active constituent of the hemp plant Cannabis sativa, confers neuroprotection in animal models of demyelination. However, the possible effect of THC on myelin repair has never been studied. Methods: By using oligodendroglia-specific reporter mouse lines in combination with 2 models of toxin-induced demyelination, we analyzed the effect of THC on the processes of oligodendrocyte regeneration and functional remyelination. Results: We show that THC administration enhanced oligodendrocyte regeneration, white matter remyelination, and motor function recovery. THC also promoted axonal remyelination in organotypic cerebellar cultures. THC remyelinating action relied on the induction of oligodendrocyte precursor differentiation upon cell cycle exit and via CB1 cannabinoid receptor activation. Conclusions: Overall, our study identifies THC administration as a promising pharmacological strategy aimed to promote functional CNS remyelination in demyelinating disorders.

  • Open Access

    Cover Image, Volume 69, Issue 3

    by Alba Huerga‐Gómez, Tania Aguado, Aníbal Sánchez‐De la Torre, Ana Bernal‐Chico, Carlos Matute, Susana Mato, Manuel Guzmán, Ismael Galve‐Roperh, Javier Palazuelos

  • Open Access

    Δ9‐Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo

    by Alba Huerga‐Gómez, Tania Aguado, Aníbal Sánchez‐De la Torre, Ana Bernal‐Chico, Carlos Matute, Susana Mato, Manuel Guzmán, Ismael Galve‐Roperh, Javier Palazuelos

    Δ9‐Tetrahydrocannabinol (THC), the main bioactive compound found in the plant Cannabis sativa, exerts its effects by activating cannabinoid receptors present in many neural cells. Cannabinoid receptors are also physiologically engaged by endogenous cannabinoid compounds, the so‐called endocannabinoids. Specifically, the endocannabinoid 2‐arachidonoylglycerol has been highlighted as an important modulator of oligodendrocyte (OL) development at embryonic stages and in animal models of demyelination. However, the potential impact of THC exposure on OL lineage progression during the critical periods of postnatal myelination has never been explored. Here, we show that acute THC administration at early postnatal ages in mice enhanced OL development and CNS myelination in the subcortical white matter by promoting oligodendrocyte precursor cell cycle exit and differentiation. Mechanistically, THC‐induced‐myelination was mediated by CB1 and CB2 cannabinoid receptors, as demonstrated by the blockade of THC actions by selective receptor antagonists. Moreover, the THC‐mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects. Our study identifies THC as an effective pharmacological strategy to enhance oligodendrogenesis and CNS myelination in vivo.


  • Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders

    by Onintza Sagredo, Javier Palazuelos, Ana Gutierrez-Rodriguez, Valentina Satta, Ismael Galve-Roperh, José Martínez-Orgado